Navigation Links
Potential cholesterol lowering drug has breast cancer fighting capabilities
Date:6/17/2014

COLUMBIA, Mo. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells.

"Cholesterol is a molecule found in all animal cells and serves as a structural component of cell membranes," said Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center at MU. "Because tumor cells grow rapidly they need to synthesize more cholesterol. Scientists working to cure breast cancer often seek out alternative targets that might slow or stop the progression of the disease, including the elimination of the cancerous cells. In our study, we targeted the production of cholesterol in cancer cells leading to death of breast cancer cells."

Previous studies suggest that 70 percent of breast cancers found in women are hormone dependent and can be treated with anti-hormone medicines such as tamoxifen. Although tumor cells may initially respond to therapies, most eventually develop resistance which causes breast cancer cells to grow and spread. Cholesterol also can contribute to the development of anti-hormone resistance because cholesterol is converted into hormones in tumor cells. Therefore, these cholesterol-forming pathways are attractive therapeutic targets for the treatment of breast cancer.

Using compounds initially developed by Roche Pharmaceuticals for the treatment of high cholesterol, which reduces cholesterol in a different manner than the widely used statins, Hyder and his team administered the molecule to human breast cancer cells. They found that the compound was effective in reducing human breast cancer cell growth and often caused cancer cell death. Most interestingly they found that the cholesterol lowering drug they tested destroyed an estrogen receptor, a prot
'/>"/>

Contact: Jeff Sossamon
sossamonj@missouri.edu
573-882-3346
University of Missouri-Columbia
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Epigenetic signatures direct the repair potential of reprogrammed cells
2. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
3. Interventional radiology: Potential breakthrough to treat mens enlarged prostate
4. Researchers report potential for a moderate New England red tide in 2012
5. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
6. Researchers find potential dark side to diets high in beta-carotene
7. Beehive extract shows potential as prostate cancer treatment
8. Gene therapy for hearing loss: Potential and limitations
9. Folic acid food enrichment potentially protective against childhood cancers
10. Nuisance seaweed found to produce compounds with biomedical potential
11. Potential new approach to regenerating skeletal muscle tissue
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Potential cholesterol lowering drug has breast cancer fighting capabilities
(Date:4/27/2015)... Conn. , Apr. 27, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... commence shipping to pre-order customers the first week of ... through the month of May. ... a significant milestone for the company as Wocket® enters ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... artificial sweeteners completely from waste water. What,s more, ... be present in our drinking water. Thanks to ... and analyses seven commonly used artificial sweeteners, Marco ... the Water Technology Center in Karlsruhe, Germany, were ...
... Plants or meat: That,s about all that fossils ... skull characteristics of a new species of parrot-beaked dinosaur ... fed on nuts and/or seeds. These characteristics present the ... "The parallels in the skull to that in ...
... The flow of water into and out from the cell ... at the University of Gothenburg, Sweden, have now found the gate ... which will be published in the journal PLoS Biology , ... growth of tumours. All living organisms must be able to ...
Cached Biology News:The bitter side of sweeteners 2Sands of Gobi Desert yield new species of nut-cracking dinosaur 2Discovery of the cell's water gate may lead to new cancer drugs 2
(Date:5/21/2015)... 2015  Susan Hedstrom, Executive Director of the ... dedicated to supporting research to advance the understanding ... that FPWR has received the organization,s largest donation ... contributed $1 million in support of the organization,s ... "Our gift signifies our tremendous ...
(Date:5/21/2015)... May 21, 2015 W. R. ... manufacturing facility in Worms, Germany has received good ... subsidiary of the International Pharmaceutical Excipient Council (IPEC) ... that produce its SYLOID® FP brand of pharmaceutical ... certification, following the Curtis Bay, Maryland (USA) and ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... upcoming poster presentation at the International Society for ... for chronic Achilles tendinosis currently in a Phase ... May 29 th from 5:30 PM to ...
(Date:5/20/2015)... This year has been one of the harshest ... Pearl’s Premium Ultra Low Maintenance Lawn Seed comes to ... coming out of record bad weather. Offering new ... concerns related to water, health, and climate change, Pearl's ... the standard, water-wasting, chemical-treated standard lawn. Many homeowners ...
Breaking Biology Technology:The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
... ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... therapeutics, today announced that it has entered ... Trop-2 Signal Transduction,Antibody Program with Laureate Pharma, ... located in Princeton, New,Jersey. ARIUS, Trop-2 antibody ...
... Products in 2008 - - Conference call to ... BRANFORD, Conn., Jan. 31 CuraGen Corporation,(Nasdaq: CRGN ) ... fiscal year ended December 31, 2007., CuraGen reported a ... million, or $0.20 per share, which included restructuring charges,totaling $2.7 ...
... report patient benefits, SUNNYVALE, Calif., Jan. 31 ... announced that it has extended,worldwide distribution of its ... the Middle East, Africa, and Asia now,have access ... wide variety,of surgical procedures., Sealing and dividing ...
Cached Biology Technology:ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 2ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 3ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 4CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 2CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 3CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 4CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 5CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 6CuraGen Reports Fourth Quarter and Year End 2007 Financial Results 7Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology 2
Adenylate kinase isoenzyme 6...
...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
... polyclonal to ZFP91 ( Abpromise ... Antigen: Synthetic peptide derived ... human ZFP91. (Note: the amino ... Entrez Gene ID: ...
Biology Products: